Autoimmune hemolytic anemia, warm type
MONDO:0019532Warm autoimmune hemolytic anemia is the most common form of autoimmune hemolytic anemia defined by the presence of warm autoantibodies against red blood cells (autoantibodies that are active at temperatures between 37-40B0C).
Also known as: Warm Autoimmune Hemolytic Anemia, wAHA, wAIHA, warm AIHA, warm antibody AIHA, warm antibody autoimmune hemolytic anaemia, warm antibody autoimmune hemolytic anemia, warm antibody hemolytic anaemia
73 clinical trials for this condition and its sub-types, 29 tagged with Autoimmune hemolytic anemia, warm type itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for rare blood disorder: drug trial targets anemia
Disease control OngoingThis phase 3 trial tests a drug called ianalumab against a placebo in 90 adults with warm autoimmune hemolytic anemia (wAIHA) who have already tried at least one treatment without success. The goal is to see if ianalumab can raise hemoglobin levels and keep them stable for at lea…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug M281 aims to tame rare blood disorder
Disease control OngoingThis study tests an experimental drug called M281 (Nipocalimab) in adults with warm autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. The trial compares M281 to a placebo to see if it can improve hemoglobin levels and reduce fatigue. About …
Phase 2/3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New pill could help patients with rare blood disorder
Disease control OngoingThis study tests an experimental drug called rilzabrutinib in 22 adults with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. Participants take the drug daily for up to 24 weeks, with an option to continue longer. The main goa…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for warm AIHA: drug trial targets blood cell destruction
Disease control OngoingThis study tests a drug called HMPL-523 (Sovleplenib) in people with warm antibody autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. About 111 adults will receive either the drug or a placebo to see if it improves hemoglobin levels and cont…
Phase 2/3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a cancer drug tame a blood disorder?
Disease control OngoingThis phase 2 trial tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have a blood condition called autoimmune hemolytic anemia (AIHA) that has come back or not responded to treatment. The study aims to see if acalabrutinib can control the ane…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Drug access program offers hope for rare blood disorder patients
Disease control Expanded access (paused)This program provides continued treatment with nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who have already shown improvement in a previous study. Participants receive the drug by IV infusion every 2 or 4 weeks. The goal is to keep their hemoglobin levels…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC